JBIO net incomeQ3 2026-$35.05M
JBIO net income was -$35.05M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$25.18M a year earlier. For the full fiscal 2025 it was -$127.41M, compared with -$69.63M in fiscal 2024.
Jade Biosciences Inc. (JBIO) financials
For the twelve months ended Sep 30, 2026, Jade Biosciences Inc. reported -$163.12M of net income.
- Net income, TTM
- -$163.12M
- Cash
- $80.39M
- Market cap
- $1.03B
FY2020FY2025
FY2021FY2025
JBIO revenue and earnings growth
JBIO EPSQ3 2026-$0.42
JBIO diluted EPS was -$0.42 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$3.19, compared with -$2.44 in fiscal 2024.
JBIO free cash flowQ4 2025-$33.65M
JBIO free cash flow was -$33.65M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$94.89M.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $93.12M | $53.19M | $64.22M | $38.62M | $14.99M | $7.94M |
| Selling, general and admin | $20.42M | $21.41M | $17.19M | $14.62M | $8.04M | $949.0K |
| Operating income | -$113.54M | -$74.60M | -$81.41M | -$53.24M | -$23.02M | -$8.89M |
| Interest expense | - | - | - | - | - | $75.0K |
| Pre-tax income | -$127.35M | -$69.57M | -$75.47M | -$51.49M | -$22.96M | -$9.61M |
| Income tax | $58.0K | $55.0K | $56.0K | $25.0K | $3.0K | - |
| Net income | -$127.41M | -$69.63M | -$75.52M | -$51.51M | -$22.96M | -$9.61M |
| EPS, basic | -$3.19 | -$2.44 | -$2.87 | -$2.10 | -$1.87 | -$40.31 |
| EPS, diluted | -$3.19 | -$2.44 | -$2.87 | -$2.10 | -$1.87 | -$40.31 |
| Diluted shares | 31.4M | 28.6M | 26.3M | 24.5M | 12.3M | 242,232 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $88.44M | $69.39M | $23.49M | $22.40M | $54.20M | $4.57M |
| Short-term investments | $247.72M | $0 | $98.95M | $106.82M | $113.18M | - |
| Current assets | $348.82M | $69.65M | $124.23M | $131.50M | $174.33M | $4.68M |
| Total assets | $349.78M | $72.80M | $127.42M | $135.30M | $175.36M | $4.71M |
| Current liabilities | $16.54M | $12.00M | $17.64M | $7.78M | $2.55M | $1.77M |
| Long-term debt | $0 | $107.60M | - | - | - | - |
| Total debt | $0 | $107.60M | - | - | - | - |
| Total liabilities | $17.26M | $119.60M | $17.96M | $8.56M | $2.94M | $1.77M |
| Shareholders' equity | $332.52M | -$46.80M | $109.46M | $126.74M | $172.42M | -$13.34M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$94.69M | -$71.20M | -$56.78M | -$39.12M | -$27.40M | -$7.86M |
| Capital expenditures | $196.0K | - | $142.0K | $195.0K | $181.0K | - |
| Free cash flow | -$94.89M | - | -$56.92M | -$39.32M | -$27.58M | - |
| Investing cash flow | -$247.01M | $56.03M | $11.88M | $6.93M | -$113.43M | - |
| Financing cash flow | $360.77M | $25.43M | $46.00M | $396.0K | $190.46M | $8.92M |
| Stock-based compensation | $20.01M | $11.31M | $11.91M | $5.48M | $2.04M | $58.0K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $30.82M | $50.06M | $36.05M | $28.54M | $22.01M | $22.55M | $20.02M | $1.53M | $13.58M | $21.25M | $20.08M | $17.81M |
| Selling, general and admin | $8.82M | $8.85M | $7.39M | $6.44M | $5.39M | $5.23M | $3.36M | $4.87M | $1.38M | $4.92M | $4.54M | $4.25M |
| Operating income | -$39.64M | -$58.92M | -$43.45M | -$34.98M | -$27.40M | -$27.78M | -$23.38M | -$6.40M | -$14.96M | -$26.16M | -$24.62M | -$22.07M |
| Pre-tax income | -$35.05M | -$55.75M | -$40.35M | -$31.87M | -$25.18M | -$32.13M | -$38.17M | - | - | - | - | - |
| Income tax | $10.0K | $15.0K | $16.0K | $58.0K | $0 | $0 | $0 | - | $0 | - | - | - |
| Net income | -$35.05M | -$55.77M | -$40.37M | -$31.93M | -$25.18M | -$32.13M | -$38.17M | -$5.43M | -$16.28M | -$24.77M | -$23.19M | -$20.41M |
| EPS, basic | -$0.42 | -$0.76 | -$0.57 | - | -$0.48 | -$0.86 | -$12.10 | - | -$5.16 | -$0.86 | -$0.83 | -$0.73 |
| EPS, diluted | -$0.42 | -$0.76 | -$0.57 | - | -$0.48 | -$0.86 | -$12.10 | - | -$5.16 | -$0.86 | -$0.83 | -$0.73 |
| Diluted shares | 71.8M | 61.1M | 57.8M | - | 39.6M | 28.4M | 3.2M | - | 3.2M | 28.8M | 27.8M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $80.39M | $107.25M | $55.09M | $88.44M | $50.11M | $220.94M | $44.22M | $69.39M | $31.11M | $31.07M | $9.12M | $23.49M |
| Short-term investments | $395.32M | $353.95M | $256.21M | $247.72M | $148.80M | - | $31.99M | $0 | $57.62M | $73.13M | $90.21M | $98.95M |
| Current assets | $485.56M | $471.25M | $318.52M | $348.82M | $201.36M | $222.98M | $77.37M | $69.65M | $90.61M | $110.76M | $103.24M | $124.23M |
| Total assets | $486.39M | $472.11M | $319.43M | $349.78M | $202.45M | $223.97M | $77.53M | $72.80M | $90.96M | $111.69M | $106.82M | $127.42M |
| Current liabilities | $30.29M | $31.57M | $22.29M | $16.54M | $22.36M | $21.62M | $2.42M | $12.00M | $10.31M | $17.02M | $15.52M | $17.64M |
| Long-term debt | - | - | - | $0 | $0 | - | - | $107.60M | - | - | - | - |
| Total debt | - | - | - | $0 | $0 | - | - | $107.60M | - | - | - | - |
| Total liabilities | $30.89M | $32.20M | $22.97M | $17.26M | $23.10M | $22.41M | $2.49M | $119.60M | $10.47M | $17.30M | $15.92M | $17.96M |
| Shareholders' equity | $455.50M | $439.92M | $296.46M | $332.52M | $179.35M | $201.56M | -$83.51M | -$46.80M | -$16.86M | -$589.0K | $90.90M | $109.46M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.91M | -$43.66M | -$24.08M | -$33.65M | -$22.12M | -$20.16M | -$18.76M | -$11.05M | -$16.04M | -$20.43M | -$23.67M | -$14.80M |
| Capital expenditures | - | - | - | $3.0K | $57.0K | - | - | - | - | - | - | $64.0K |
| Free cash flow | - | - | - | -$33.65M | -$22.18M | - | - | - | - | - | - | -$14.86M |
| Investing cash flow | -$42.30M | -$97.63M | -$8.47M | -$98.16M | -$148.71M | -$12.99M | $12.85M | $13.13M | $16.07M | $18.00M | $8.83M | $5.65M |
| Financing cash flow | $44.35M | $193.52M | -$795.0K | $170.16M | $0 | $191.31M | -$700.0K | $554.0K | $22.0K | $24.38M | $471.0K | $463.0K |
| Stock-based compensation | $7.07M | $13.61M | $7.41M | $9.40M | $4.29M | $3.90M | $2.42M | $1.24M | $2.00M | $3.87M | $4.20M | $3.25M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 16.03 | 14.93 | 14.29 | 21.09 | 9.01 | 10.31 | 32.01 | 5.81 | 8.78 | 6.51 | 6.65 | 7.04 |
| Debt to equity | - | - | - | 0.00 | 0.00 | - | - | - | - | - | - | - |
Source: XBRL data Jade Biosciences Inc. files with the SEC, latest filing dated Nov 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
JBIO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| JBIO | - | - | -$163.12M | - | $1.03B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.36T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $687.89B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $521.50B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.26B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $306.26B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $286.03B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $187.95B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $184.33B |
JBIO FAQ
4 questionsIs JBIO profitable?
No. Jade Biosciences Inc. reported a net loss of $163.12M for the twelve months ended Sep 30, 2026.How much cash and debt does JBIO have?
Jade Biosciences Inc. reported $80.39M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did JBIO last report financial results?
The latest statements here come from Jade Biosciences Inc.'s 10-Q filed on Nov 13, 2026, covering the period ended Sep 30, 2026.Where does this JBIO financial data come from?
Quantisnow builds these statements from the structured XBRL data Jade Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.